Our laboratory investigates the molecular genetic basis of human
brain tumors, with a focus on the molecular genetics of sporadic
malignant gliomas. Elucidating the molecular basis of glioma formation
may impact both on diagnostic and therapeutic aspects of clinical
neuro-oncology. For instance, we originally demonstrated that molecular
genetic analysis could be used to define clinicopathologically relevant
subsets of glioblastomas. In addition, we have recently shown that
molecular genetic alterations are powerful predictors of chemotherapeutic
response and survival in patients with anaplastic oligodendrogliomas.
We are also engaged in positional cloning of a tumor suppressor
gene on chromosome 19q, which may be a glial-specific tumor suppressor
gene.
The laboratory is also involved in
molecular genetic study of other forms of primary human brain tumors,
including medulloblastomas, meningiomas, schwannomas and hemangiopericytomas.
In particular, we have studied the genetic basis of certain inherited
neurological tumor syndromes, such as neurofibromatosis 2, which
predispose patients to develop tumors such as schwannomas and meningiomas.
The laboratory also serves as a reference
laboratory for standard pathological and immunohistochemical analysis,
including for ongoing studies of gene therapy in patients with glioblastomas.